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ABSTRACT 
 
The feline homologue of CD134 (fCD134) is the primary binding receptor for feline 
immunodeficiency virus (FIV), targeting the virus preferentially to activated CD4+ 
helper T cells.  However, with disease progression, the cell tropism of FIV broadens 
such that B cells and monocyte/macrophages become significant reservoirs of proviral 
DNA, suggesting that receptor utilisation may alter with disease progression.  We 
examined the receptor utilisation of diverse strains of FIV and found that all strains 
tested utilised CD134 as primary receptor. Using chimaeric feline x human CD134 
receptors, the primary determinant of receptor function was mapped to the first 
cysteine rich domain (CRD1) of fCD134. For the PPR and B2542 strains, substitution 
of CDR1 of fCD134 (amino acids 1 to 64) into human CD134 (hCD134) alone was 
sufficient to confer near optimal receptor function. However, evidence of differential 
utilisation of CD134 was revealed since GL8, CPGammer (CPG41), TM2, 0827 and 
NCSU1 required determinants in the region spanning amino acids 65-85, indicating 
that these strains may require a more stringent interaction for infection to proceed. 
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INTRODUCTION 
 
 The initial event in the process of viral entry into a target cell is the interaction 
between the virus and its cellular receptor and the specificity of this interaction  
determines both the cell tropism and the pathogenicity of the virus.  The primary 
receptor for HIV and SIV is CD4, targeting the virus to helper T cells and resulting in 
progressive depletion of these cells and the eventual development of AIDS46.  
However, CD4 expression alone is insufficient to confer susceptibility to infection 
with HIV, which also depends on expression of co-receptors, principally the 
chemokine receptors CXCR4 and CCR53. The virus attaches via a high affinity 
interaction with CD4, resulting in a conformational change in the envelope 
glycoprotein (Env) and exposing the binding site for the chemokine receptor30. This 
then triggers a further conformational change that exposes the fusion domain of the 
viral transmembrane protein gp41 and enables fusion of the viral and cellular 
membranes17. 
The feline immunodeficiency virus (FIV) is unique among the non-primate 
lentiviruses because in its natural host species, the domestic cat, it induces a disease 
similar to AIDS, characterised by a progressive depletion of CD4+ T lymphocytes39.  
In chronic infection, an immunodeficiency syndrome develops that is characterised by 
wasting, neurological manifestations, chronic stomatitis and gingivitis and an 
increased incidence of lymphoma38. In contrast, the ungulate lentiviruses induce 
diseases reminiscent of chronic inflammatory conditions. However, CD4 is not the 
primary receptor for FIV, the primary receptor was revealed recently to be CD134 
(OX40)48, a member of the tumour necrosis factor receptor/nerve growth factor 
receptor superfamily. Primary isolates of FIV use CD134 as the binding receptor in 
conjunction with the chemokine receptor CXCR4 as a co-factor for infection45,48,60. 
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FIV binds specifically to CD134-expressing cells48, the FIV Env interacts directly with 
CD13412 and pre-treatment of virus with sCD134 facilitates infection of CD134-ve / 
CXCR4+ve cells11.  
CCR5 appears to be the co-receptor utilized by the majority of HIV strains 
early in infection, usage of CXCR4 as a co-receptor is more frequent with disease 
progression10,47.  In contrast, FIV appears to use CXCR4 alone as its sole co-receptor 
for infection19,45,61 and yet with disease progression the viral cell tropism expands14,20 
suggesting an alteration in receptor utilisation.  Previous studies have demonstrated 
that upregulation of endogenous CXCR4 can increase susceptibility to infection with 
FIV59 and that over-expression of exogenous human CXCR4 on a target cell may 
overcome the requirement for the expression of CD13413. Thus it is possible that with 
disease progression, FIV may either lose its dependence on an interaction with 
CD134, or interact more efficiently with CXCR4.  
In this study we investigate the use of CD134 as a functional receptor by 
diverse strains of FIV. As a first step towards understanding the role of CD134 in the 
pathogenesis of FIV infection, we examine the receptor utilisation of a panel of FIV 
isolates of diverse subtypes and geographical origins. We define the region of CD134 
that confers functional FIV receptor activity and present evidence for differential 
usage of CD134 as a viral receptor by diverse strains of FIV. 
 
CD134 utilisation by FIV 
5 
MATERIALS AND METHODS 
 
 
Cells and viruses.  MYA-133 , MCC7 and NSO  were cultured in RPMI 1640 
medium.  293T and HeLa were maintained in Dulbeccos modification of Eagle’s 
medium (DMEM). All media were supplemented with 10% foetal bovine serum 
(FBS), 2mM glutamine, 0.11mg/ml sodium pyruvate 100 IU/ml penicillin, 100 μg/ml 
streptomycin. The medium for MYA-1 cells was supplemented with conditioned 
medium from a murine cell line (L2.3) transfected with a human IL-2 expression 
construct (equivalent to 100 U/ml of recombinant human IL-2) and 50μM 2-
mercaptoethanol.  All media and supplements were obtained from InVitrogen Life 
Technologies Ltd. (Paisley, UK). Cell lines expressing CD134 and the chimaeric 
constructs were maintained in G418 (InVitrogen, Paisley, UK). The canine 
lymphocytic leukemia (CLL) cell line was generated by prolonged in vitro culture of 
peripheral blood mononuclear cells, the established line is CD3+ve/CD4-ve/CD8-ve. 
 The B254215 (subtype B) and CPGammer16 isolates of FIV (subtype C) were 
obtained from E. Hoover and S. Vandewoude. Molecular clones of TM21932  and 
NCSU1 (JSY3)63 were from T. Miyazawa and W. Tompkins respectively. PPR41 Env 
was (plasmid  pΔ1137 ) was obtained from G. Pancino. pFIV-PPR was obtained from 
the NIH AIDS Research & Reference Reagent Program, Division of AIDS, NIAID, 
NIH: from Dr John Elder. GL824, 0827, 0425 and 1419 are subtype A field isolates of 
FIV from the United Kingdom. 
 
Antibodies and flow cytometry.  Anti-human CD134 (BerACT35) was obtained 
from Alexis Corporation. Anti-human CXCR4 (#44701) was obtained from R&D 
Systems, Abingdon, Oxford, United Kingdom. Cells to be processed for flow 
cytometry were resuspended in phosphate buffered saline (PBS) supplemented with 
1.0% (w/v) bovine serum albumin, 0.1%  (w/v) sodium azide (PBA). Cells were 
incubated with 1μg of primary antibody for 30 minutes at 4oC and then washed twice 
with PBA by centrifugation at 1000 rpm for 5 minutes. Bound primary antibody was 
detected with the appropriate anti-mouse IgG secondary antibody (Serotec, Oxford, 
United Kingdom) corresponding to the isotype of the primary antibody and 
conjugated to either fluorescein isothiocyanate (FITC) or R-phycoerythrin (RPE). 
Cells were incubated with secondary antibody for 30 minutes at 4oC and then washed 
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twice with PBA by centrifugation at 1000rpm for 5 minutes and resuspended in 1ml 
of PBA for analysis. All samples were analysed on a Beckman Coulter EPICS MCS-
XL flow cytometer, 10,000 events being collected for each sample in LIST mode. 
Data were analysed using EXPO 32 ADC Analysis (Advanced Cytometry Systems). 
 
Construction of feline x human CD134 chimaeras.  Previously, we demonstrated 
that feline, but not human CD134, supported infection with FIV48. The amino acid 
sequences of feline and human CD134 were aligned using the Clustal W algorithm55, 
enabling the identification of non-conserved amino acids, many of which were 
localised to the N-terminal (extracellular) region of the molecule. The predicted three 
dimensional structure of feline CD134 was generated using Swiss-Model40 in first 
approach mode and images were then manipulated using Swiss-PdbViewer v3.7b2 
(Glaxo Wellcome Experimental Research). The 3D structure prediction enabled the 
identification of non-conserved amino acids that were either within, or in close 
proximity to the N-terminal cysteine-rich domains (CRDs). A strategy was therefore 
devised that would enable the generation of feline x human chimaeric CD134 
molecules creating chimaera junctions in conserved regions of amino acid sequence, 
preserving the sequence and thus being less likely to affect the tertiary structure of the 
chimaeric protein. To facilitate the construction of these chimaeras, NruI and BsrGI 
restriction sites were introduced into the feline and human CD134 cDNA clones by 
using the polymerase chain reaction (PCR) and the primers 5- CCAATA 
CCCTACCTCAGCGCTACGTCG-3’ (NruI) and  5’-GGCACGTTCGGGACATGT-
3’ (BsrGI).  These restriction sites created chimaera junctions between residues 56 
and 57, and 85 and 86 of feline CD134. Thus chimaera “FHF” represents “feline 
CD1341-56 x human CD13457-85 x feline CD13486-270”. Additional chimaeras were 
prepared in which amino acids 47 to 56 of human CD134 were introduced into 
chimaera FFH, generating (FH)FH, and in which amino acids 65 to 85 of feline 
CD134 were introduced into chimaera FHH, generating F(FH)H. The nucleic acid 
sequence of each of the chimaeric CD134s was confirmed by cycle sequencing on an 
Applied Biosystems 9700 thermal cycler using a BigDye® Terminator v1.1 cycle 
sequencing kit (Applied Biosystems) followed by analysis on an Applied Biosystems 
3700 genetic analyser. cDNAs were subcloned into the retroviral vectors pDONAI 
(Takara, Tokyo, Japan) and pCNC-MCS25.  
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In order to generate CD134-EGFP gene fusions, the coding sequences for the 
CD134s and CD134 chimaeras were re-amplified with the primers 5’-TT 
GGTACCATGAGGGTGGTTGTGGGGGCT-3’ (KpnI) and 5’-ATCCCGGGCGA 
TCTTGGCCAGGGTGGAGTT-3’ (SmaI) and cloned into pEGFPN1 (BD 
Biosciences Clontech, Cowley, Oxford, UK). The resulting gene fusion was then 
subcloned into pDONAI or pCNC-MCS25. The nucleic acid sequence of all gene 
fusions was confirmed as above. 
 
HIV pseudotype assays.  FIV env gene expression constructs GL8, 0827, 0425, 
1419, PPR and TM2 have been described previously48.  B2542 and CPGammer envs 
were amplified by PCR from DNA prepared from infected MYA-1 cells and cloned 
directly into VR1012 (Vical Inc., San Diego, CA). 5μg of each VR1012-env, 
NCSU1env-cDNA321 or pCI-VSV-G, and 7.5μg of pNL4-3-Luc-E−R− were co-
transfected into HEK-293T cells using the Calcium-Phosphate co-precipitation 
technique essentially as described previously23. Culture supernatants were collected at 
48 hours post-transfection, filtered at 0.45μm and frozen at –70oC until required. 
Adherent target cell lines were seeded at 1x104 cells per well of a CulturPlateTM-96 
assay plate (Perkin Elmer, Life and Analytical Sciences, Beaconsfield, UK) and 
cultured overnight, while suspension target cell lines were seeded at 5x104 cells per 
well and used immediately. The cells were then infected with 50μl HIV (FIV) 
luciferase pseudotypes, cultured for 72 hours and then luciferase activity quantified by 
the addition of 50μl of Steadylite HTSTM (Perkin Elmer) luciferase substrate and 
measurement by single photon counting on a MicroBeta luminometer (Perkin Elmer).    
 
Growth of FIV in vitro.  The growth of FIV in vitro was assessed in MCC cells 
transduced with each of the chimaeric CD134 constructs.  1x106 cells were infected 
with 0.45μm-filtered culture supernatant from FIV infected MYA-1 cells containing 
approximately 10,000 TCID50 (titred on MYA-1 cells) of virus for 2 hours at 370C. 
The cells were then pelleted by centrifugation at 1000rpm, the medium aspirated and 
the cells washed twice with PBS. The cells were then resuspended in culture medium 
and plated in 12 well culture plates. Supernatants were collected every three days and 
assayed for reverse transcriptase (RT) activity using Lenti-RT non-isotopic RT assay 
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kit (Cavidi Tech., Uppsala, Sweden). RT values were then calculated relative to 
purified HIV-1 RT standard.   
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RESULTS 
 
BerACT35 recognises feline CD134. 
 
  Previous studies have used the anti-human CD134 monoclonal antibody 
BerACT35 to monitor CD134 expression on feline cells22,26,48, demonstrating that 
fCD134 is expressed on IL2-dependent T cells in vitro48 and on CD4+/CD25+ Treg 
cells in vivo26. However recent studies have asserted that the BerACT35 antibody is 
human CD134-specific and does not recognise feline CD13411,12. Given that the 
ability to monitor surface expression of CD134 is critical to the interpretation for 
assays of receptor function, and in order to resolve these discordant findings, we 
examined the binding of BerACT35 to feline, human and murine cells stably 
transduced with retroviral vectors bearing feline CD134 (Fig.1). Feline CD134-
expressing feline cells (MCC, Fig. 1a), human cells (NP2, Fig.1b) and murine cells 
(NSO, Fig. 1c) cells displayed strong, specific binding of BerACT35 following stable 
transduction with the feline CD134 expression vector. To further confirm the 
specificity of the interaction, MCC cells were stably transduced with a retroviral 
vector bearing a feline CD134/C-terminal EGFP fusion (Fig. 1d).  The majority of 
BerACT35 reactivity (CD134-PE, 74.3%) was directly proportional to intensity of 
CD134-EGFP expression.  Finally, BerACT35 reacted with CrFK cells following 
either transient transfection (Fig. 1e, 5.7% double positive for CD134-
EGFP/BerACT35 PE) or stable transduction (Fig. 1f, 55.6% double positive for 
CD134-EGFP/BerACT35 PE) with feline CD134-EGFP expression vectors. These 
data are consistent with BerACT35 recognising feline CD134 irrespective of the 
cellular target and means of ectopic expression. 
  Given that BerACT35 binds specifically to feline CD134, we examined the 
effect of infection with subtype A, B and C viruses on CD134 expression on IL2-
dependent feline T cells (MYA-133). MYA-1 cells were infected with the GL824, 
B254215 and CPGammer16 strains of FIV (subtypes A, B and C respectively) and 
monitored by flow cytometry for expression of CD134 and CXCR4. In parallel, 
supernatants were collected to measure reverse transcriptase (RT) activity. FIV 
infection resulted in a sharp decline in CD134 expression within 2 days post-infection 
(Fig. 2b., c. and d.) irrespective of the viral subtype. The reduction in CD134 
expression mirrored a rise in RT production and persisted for the duration of the time 
course. In contrast, CD134 expression remained relatively stable on the uninfected 
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control cells (Fig. 2a.). Similar findings were observed with CXCR4 expression, a 
sharp decline in CXCR4 expression (Fig. 2g., h. and i.) mirroring the concomitant rise 
in RT production. However, the reduction in CXCR4 expression did not persist, 
expression levels recovering to control levels by the end of the time course. These 
results would be consistent with the expansion of a CD134-negative and FIV-resistant 
population of cells. To further address the specificity of the fall in CD134-expression 
in FIV-infected cells, MYA-1 cells were infected with the non-domestic cat 
lentiviruses PLV (puma lentivirus) and LLV (lion lentivirus). There was no reduction 
in CD134 expression in either PLV (Fig. 2c.) or LLV (Fig. 2f.) infected cells, indeed 
PLV infection resulted in an increase in expression of both CXCR4 (Fig. 2i.) and 
CD134 suggesting an increase in the activation state of the T cells (both CXCR4 and 
CD134 are up-regulated on activated T cells).  The data suggest that the reduction in 
CD134 expression following FIV infection is specific to the domestic cat virus. 
 
Expression of CD134 chimaeras. 
 
  In order to discern whether diverse isolates of FIV interacted with CD134 in a 
similar way, we mapped the functional determinants of receptor activity on feline 
CD134 using series of chimaeras generated between human and feline CD134 
(previously, we had demonstrated that human CD134 did not support infection with 
FIV48). Chimaeras were designed based on the predicted three-dimensional structure 
of feline CD134 generated by submitting the feline CD134 amino acid sequence 
translation to the SWISS-PROT server in First Approach mode. The predicted 
structure of fCD134 was compared with that of the TNFR2 and herpes simplex virus 
entry mediator (HveA)6,8,9. Given the distribution of divergent amino acid residues 
between feline and human CD134, the most likely site for interaction between FIV 
Env and CD134 was predicted to lie in the first cysteine-rich domain (CRD1), 
analogous to the binding site for HSV gD on HveA6,8,9.  Chimaeras were therefore 
designed such that the junctions were located in regions of sequence conservation 
between the human and feline CD134 translations and focused primarily on the first 
and second CRDs (Fig.3). The CRD definitions are as described previously31 and 
correspond to the molecular architecture A1B2 (CRD1 and CRD2) and A1B1 (CRD3)  
as detailed previously5.  The nucleic acid sequence of each chimaera in the retroviral 
vector was confirmed prior to stable transduction of the target cell line (MCC). 
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Surface expression of each chimaera was assessed using BerACT35 antibody.  Of the 
seven constructs, five were stably expressed on the cell surface in a form that was 
recognised by BerACT35; namely FFF, FFH, FHF, FHH and HHF (Fig. 4). Two 
chimaeras (HFF and HFH) appeared to express poorly at the cell surface and 
moreover the cell lines bearing these molecules took longer to expand following G418 
selection, perhaps indicating an inhibitory effect on cell growth.  To ascertain whether 
the HFF and HFH chimaeras were being expressed, we generated a second series of 
cell lines in which the C-termini of the CD134 constructs were tagged with EGFP. 
Transduction of MCC cells with the GFP-tagged CD134 constructs indicated that the 
constructs were indeed being expressed, but that expression was not being detected at 
the cell surface by BerACT35 (data not shown), indicating that either the molecule 
did not reach surface of the cells or the BerACT35 epitope had been disrupted in these 
cells.  
 MCC cells transduced with the CD134 chimaeras were infected with HIV (FIV) 
pseudotypes carrying a luciferase marker gene (HIV(FIV)-luc) and bearing Envs from 
the GL8, PPR and TM2 strains of FIV (Fig. 5). Viral entry was detected in two of the 
eight cell lines; FFF (the reconstructed full length CD134) and FFH (feline CD1341-85 
x human CD13486-270). All chimaeras bearing amino acids 57 to 85 of human CD134 
were rendered non-functional as viral receptors, despite encoding CD134 molecules 
that were stably expressed on the surface of the transduced cells that could be detected 
with BerACT35. Thus chimaera FFH was a functional receptor whereas FHH was 
not. These data indicated that the region spanning amino acids 1 to 86 conferred FIV 
receptor activity to feline CD134. Amino acids 1 to 86 comprise CRD1 and part of 
CRD2 and encompass the region known to form the binding domain for gD on HveA. 
To further define the region that conferred functional receptor activity on CD134, we 
prepared two additional chimaeras exchanging amino acids 47 to 56 and 65 to 85 
between chimaeras FFH and FHH, generating chimaeras F(FH)H and (FH)FH (see 
Fig.3). MCC cells were transduced with retroviral vectors bearing the novel 
chimaeras, stably selected (cell surface expression of the chimaeras was confirmed 
using BerACT35, not shown) and challenged with HIV (FIV) luc pseudotypes bearing 
the GL8, PPR and TM2 Envs (Fig. 6). Chimaera F(FH)H, which effectively contains 
CRD1 of feline CD134 in the context of human CD134, almost completely lost the 
ability to act as a functional receptor for infection mediated by the GL8 or TM2 Envs 
(Fig. 6a. and c., 0.0% and 0.4% of FFF control). In contrast, infection mediated by 
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PPR Env was supported with reduced efficiency (Fig. 6b, 3.8% of FFF control). 
Chimaera (FH)FH was more effective as a functional receptor supporting viral entry 
mediated by the GL8, PPR and TM2 strains (16.5, 39.3 and 21.4% of FFF control). It 
has been reported that substitution of the region defined as CRD1 from feline CD134 
into human CD134 (equivalent to chimaera F(FH)H) is sufficient to confer full 
receptor function for  a single isolate of FIV11. The data with chimaeras F(FH)H and 
(FH)FH are consistent with CRD1 containing a major component of the receptor 
binding domain. However, for reconstitution of a functional receptor, additional 
determinants outwith CRD1 are clearly required. Given that F(FH)H did not support 
infection with the GL8 and TM2 pseudotypes while showing reduced activity with 
PPR  pseudotypes, a broader range of pseudotypes was investigated for usage of the 
chimaeric receptors. Pseudotypes were prepared bearing Envs prepared from the 
highly pathogenic subtype C virus FIV-CPGammer16 (CPG41); the subtype A isolates  
1419 and 082748; and subtype B NCSU163 and B254215 strains of FIV. The CPG41 
and NCSU1  (Fig. 6d. and h.) strains yielded similar results to the GL8 and TM2 
strains; chimaera (FH)FH supporting viral entry mediated by CPG41, 1419, 0827 and 
NCSU1 Envs  (32%, 21, 21 and 38% of FFF control respectively) while F(FH)H had 
no or low activity (0.0%, 3.6%, 0.0%  and 0.9% of FFF control). In contrast, the 
subtype B isolate, B2542 (Fig. 6e.) yielded findings to PPR, utilizing both the (FH)FH 
and F(FH)H chimaeras efficiently (76% and 24% of FFF control) .   The data suggest 
that determinants outwith CRD1 in the region spanning amino acids 65 to 85 are 
required to form a functional receptor for the majority strains of virus. That chimaera 
F(FH)H showed activity with the B2542 and  PPR strains may provide evidence for 
the utilisation of distinct regions of CD134 by diverse strains of FIV.   
 Additional cell lines stably expressing the (FH)FH and F(FH)H constructs and 
based on the cell line HeLa were generated in order to assess the reproducibility of the 
findings with MCC - (FH)FH and F(FH)H (MCC cells are feline lymphoid cells while 
HeLa cells are human epithelioid cells).  The cells were then challenged with HIV 
(FIV) luc pseudotypes bearing a range of Envs, the results are summarised in table 1 
with receptor function expressed as “–fold increase” in susceptibility relative to cells 
transduced with vector only. Strains GL8, CPG41, TM2, 0827 and NCSU1 showed a 
preference for chimaera (FH)FH over F(FH)H, most marked with the FIV-
CPGammer16 (CPG41) Env which  used (FH)FH 59-fold and 269-fold more 
efficiently than F(FH)H in MCC and HeLa cells respectively. The data confirm that 
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determinants in the region spanning amino acids 65 to 85 of CD134 are required for 
to viral entry to proceed. 
 We next asked whether cells expressing the (FH)FH and F(FH)H chimaeras 
showed differences in their ability to support productive infection (Fig. 7). CLL cells 
expressing the chimaeric receptor molecules were infected with matched doses of the 
cloned viruses GL8 and GL8.CPG41 (preference for FHFH) and GL8.B2542 and PPR 
(no preference or weak preference). Cells were infected in parallel with HIV(FIV) 
pseudotypes bearing the equivalent Envs. Whereas assays using viral pseudotypes 
measure viral entry alone, cell-free virus infection represents the sum of entry, 
replication, egress and cell-to-cell spread.  Therefore we predicted that the efficiency 
of the chimaeras as viral receptors might be less evident in an assay for productive 
virus infection. HIV (FIV) pseudotypes bearing the GL8 and CPG41 Envs used 
chimaera FHFH with greater efficiency than FFHH in CLL cells while PPR or B2542 
pseudotypes used both FHFH and FFHH efficiently (Fig. 7a.), consistent with 
previous findings using MCC and HeLa cells transduced with the FFHH and FHFH 
expression vectors (Table 1). It was notable that viral entry into the vector only 
control CLL cells was ~10-fold higher than for GL8, PPR and B2542 than for CPG41. 
These data may suggest upregulation of endogenous canine CD134 during the 
selection process; studies are currently underway to address whether this is indeed the 
case. 
 Productive infection experiments recapitulated these findings in that GL8 and 
GL8.CPG41 replicated more efficiently in CLL-FHFH cells than CLL-FFHH. GL8-
B2542 and PPR did not display a preference for CLL-FHFH over CLL-FFHH, indeed 
B2542 replicated more efficiently in CLL-FFHH than in CLL-FHFH (Fig.7b.) 
suggesting that in this system, the selectivity for the two chimaeras extended into 
replicative capacity.  
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DISCUSSION 
 
The virus-receptor interaction is the primary event in the viral replicative cycle, a 
major determinant of cell tropism and a target for therapeutic intervention. Antibodies 
that block the HIV-CD4 interaction have been shown to have broad neutralising 
activity (anti-CD4 binding site antibodies); neutralising strains of virus from diverse 
clades and geographical origins. In this study we investigated the binding site for FIV 
Env on CD134, the cellular receptor for FIV. We show primary isolates of FIV can be 
classified into at least two groupings based on their interaction with CD134. 
Expression of feline CD134 CRD1 alone in the context of human CD134 is sufficient 
to confer near optimal receptor function for infection with strains such as PPR, in 
agreement with recent findings11. However, pathogenic primary strains of virus such 
as GL8, CPGammer and NCSU1 require additional determinants in CRD2 for 
restoration of receptor function. These data provide the first evidence for differential 
utilisation of feline CD134 by FIV.  The extent of the binding site utilised by strains 
such as GL8, CPGammer and NCSU1 remains to be established; substitution of 
amino acids S60D, N62D, H45S, R59G and V64K in human CD134 recreated the 
binding site for FIV PPR Env and restored infectivity for CrFK cells, in contrast 
chimaera F(FH)H in this study (containing all the above amino acids) had near 
negligible activity as a receptor for Envs GL8 and CPG41.  The PPR strain infects 
CrFK cells with a low efficiency in the absence of CD13411, and over-expression of 
human CXCR4 alone is sufficient to render (CD134-negative) G355 cells permissive 
for productive infection with FIV PPR13. These data may indicate either a reduced 
requirement for CD134 or a reduced threshold for induction of the conformational 
change in the PPR Env that permits a direct interaction with CXCR4. Consistent with 
this hypothesis, an FIV PPR SU-Fc fusion protein bound to 60% of purified resting 
feline PBMC and the majority of binding was via CXCR4 alone12 suggesting that 
viruses such as PPR may have a low requirement for CD134 for binding/infection. A 
reduced activation threshold for envelope-mediated fusion has been implicated in the 
propensity for CD4-independent infection by HIV-244.  Given that the interaction 
between the GL8, CPG41 and NCSU1 Envs would appear to be more complex than 
that of PPR, extending outwith CRD1, our studies raise the possibility that infection 
by such viruses may well be modulated by the natural ligand for feline CD134 
(CD134L or OX40 ligand). 
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 The interaction between HIV and CD4 induces a conformational change in gp120 
that results in the exposure of the chemokine receptor binding site, this 
conformational change being marked by the exposure of epitopes for CD4i (CD4-
induced) antibodies such as 17b and 48d30,50,51,53,62. Primary strains of HIV become 
more sensitive to sCD4 with prolonged culture1,34,35. With the discovery of the co-
receptors CXCR4 and CCR5, it became apparent that X4 variants of HIV were more 
sensitive to surface CD4 concentration than R5 strains of virus29. Subsequently, the 
affinity of the interaction between Env and CD4 was shown to be critical to the 
process of adaptation to cell culture42 and primary and laboratory-adapted strains of 
HIV were shown to display differential requirements for levels of both CD4 and 
CXCR456.  By analogy with HIV, our data may indicate that some primary strains of 
FIV may require a more complex interaction with CD134 than others for infection to 
proceed. Although at present the reagents with the interaction between these primary 
Envs and CD134 may be dissected are not currently available, future studies should 
investigate whether the complexity of the interaction between Env and CD134 for 
strains such as GL8 is reflected in an increased (or decreased) binding affinity for 
CD134. An increased affinity for CD4 has been shown to accompany laboratory 
adaptation for HIV42.  One of the FIV strains (PPR) able to utilise the fCD134 CDR1-
only chimaera has been shown previously to infect CD134-negative feline cells in the 
following over-expression of human CXCR413. Although human CXCR4 does have 
an intrinsically higher activity as a co-receptor for FIV than feline CXCR458, these 
data may indicate that strains such as PPR, with a less stringent interaction with 
CD134, may be more readily adapted for culture in CD134-negative cell lines. 
Moreover, the emergence of such strains in vivo may accompany a broadening of the 
viral cell tropism as has been observed with the shift from acute to chronic FIV 
infection14,20. The link between the nature of the Env-CD134 interaction and the 
broadening of viral cell tropism with disease progression will an important avenue of 
future research. 
 The surface expression of feline CD134 and the feline x human CD134 chimaeras 
was monitored using the anti-human CD134 antibody BerACT35 and yet previous 
studies11,12 have suggested that this antibody is human-specific. Given the importance 
of this reagent to the study of the virus-receptor interaction it is crucial that these 
discordant observations be reconciled. BerACT35 has been used to monitor feline 
CD134 expression in vitro and in vivo22,26,48. Further, we have shown that surface 
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CD134-expression can be evaluated using BerACT35 following stable transduction of 
the adherent cell lines HeLa, NP2 and AH927, or suspension cells NSO, MCC or 
3201 with retroviral vectors bearing feline CD134, suggesting that using this system 
feline CD134 is expressed in the same conformation as the endogenously expressed 
molecule.  The studies in which BerACT35 failed to recognise feline CD13411,12 were 
performed using transient retroviral transduction of CrFK cells; it is possible that in 
such an expression system feline CD134 may be expressed in a distinct antigenic 
conformation, a conformation distinct from that present in vivo26.  The significance of 
these distinct antigenic conformations to FIV receptor function remains to be 
established however given that BerACT35 recognises feline CD134 in vivo, this 
antigenic conformation is likely to be biologically relevant. 
 CD4-independent strains of HIV are particularly sensitive to neutralizing 
antibodies18,27,28,43 and thus may be more likely to arise where the host humoral 
immune response is failing, or in immunoprivileged sites (reviewed in ref. 4). CD134-
independent strains of FIV are readily neutralised by sera from infected animals, most 
markedly when the assays are performed on CD134-negative/CXCR4-positive cells36. 
Similarly, neutralising antibodies against CD4-independent strains of HIV/SIV are 
detected more readily when the assays are based on CD4-negative cells43,54. Many of 
the prototypic strains of FIV were either isolated from animals with clinical signs of 
AIDS39,41 or have subsequently undergone prolonged culture in vitro49,52,57, with the 
consequence that a degree of selection for neutralisation-sensitive strains of virus with 
a propensity for adaptation to CD134-independent infection. Given that the in vivo 
cell tropism of FIV would appear to expand with disease progression14,20,  it is likely 
that the strains of virus present in animals displaying clinical signs may differ from 
those present in the early/acute phase of infection, analogous to the shift in cell 
tropism observed with the emergence of X4 strains of HIV with the progression to 
AIDS10. Future studies should address whether strains of FIV present in the early 
acute phase of infection differ in in vitro cell tropism and receptor usage from those 
isolated from animals displaying clinical signs. Vaccine efforts may then be targeted 
against the strains of virus that are most likely to be transmitted between animals. 
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Figure legends 
 
Figure 1.  BerACT35 recognises feline CD134.  BerACT35 reactivity was assessed by 
flow cytometry on a) MCC (feline), b) NP2 (human) and c) murine (NSO) cells stably 
transduced with either fCD134.pDONAI (filled histogram) or pDONAI vector only 
(open histograms).  Reactivity was also assessed on MCC (D) and CrFK (F) cells 
stably transduced, and CrFK cells (E) transiently transfected with 
fCD134.EGFP.pDONAI.  
 
Figure 2.  Reduced surface expression of CD134 and CXCR4 in FIV infected cells. 
Surface expression of CD134 (a.-f.) and CXCR4 (g.-l.) expression was monitored by 
flow cytometry using anti-CD134 (BerACT35) and anti-CXCR4 (RND44701) in IL2-
dependent T cells infected with FIV strains GL8 (b.,h.), B2542 (d.,j.) and CPGammer 
(e.,k.), the puma lentivirus PLV (c.,i), the lion lentivirus LLV (f.,l) or  mock-infected 
(a.,g.). Percentage positive was calculated relative to isotype-matched control. 
Supernatants were collected in parallel and reverse transcriptase (RT) activity 
estimated by non-isotopic assay, results are expressed as absorbance 405nm. 
 
Figure 3.  Construction of feline x human CD134 chimaeras.  a.) Predicted 3D 
structure of feline CD134, comparison with TNFR and HveA, location of CRD1 and 
CRD2. b.) Schematic of feline x human CD134 chimaeras showing the location of the 
junctions between the feline (grey) and human (white) regions. Numbered arrows 
indicate amino acids flanking the junctions.  
 
Figure 4.  Surface expression of CD134 chimaeras. MCC cells were stably transduced 
with a retroviral vector bearing each chimaera. Cell surface expression of CD134 was 
analysed by flow cytometry using BerACT35. Each histogram represents 10,000 
events and is representative of two analyses. 
 
Figure 5.  Ability of CD134 chimaeras to act as functional receptors for FIV.  MCC 
cells stably transduced with a retroviral vector (pDONAI) bearing each of the 
chimaeras, or vector only (CON), were infected with HIV (FIV) luciferase 
pseudotypes bearing the GL8, PPR or TM2 Envs. Luciferase activity was assayed at 
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72 hours post-infection and is expressed as mean (n=3) counts per minute (CPM) +/- 
SE.  
 
Figure 6. Differential utilisation of CD134 chimaeras by FIV.  MCC cells stably 
transduced with a retroviral vector (pDONAI) bearing each of the chimaeras (FFF, 
(FH)FH, F(FH)H, HHH or vector only (CON), were infected with HIV (FIV) 
luciferase pseudotypes bearing the GL8 (a), PPR (b), TM2 (c), CPG41 (d), B2542 (e), 
1419 (f), 0827 (g)  and NCSU1 (h) Envs. Luciferase activity was assayed at 72 hours 
post-infection and is expressed as   mean (n=3) counts per minute (CPM) +/- SE.  
 
Figure 7. Productive infection of cells expressing CD134 chimaeras. a). CLL cells 
stably transduced with a retroviral vector (pDONAI) bearing each of the chimaeras 
(FFF, (FH)FH, F(FH)H  or vector only (CON), were infected with HIV (FIV) 
pseudotypes bearing the GL8, B2542, CPG41 and PPR Envs and assayed for viral 
entry by luciferase assay. Luciferase activity was assayed at 72 hours post-infection 
and is expressed as   mean (n=3) counts per minute (CPM) +/- SE. B.) Cells were 
infected in parallel with matched titres of replication competent virus from the 
molecular clones GL8, GL8.2542, GL8.CPG41 and PPR; supernatants were collected 
at days 0, 1, 4 and 6 post-infection and assayed for virus production by non-isotopic 
reverse transcriptase activity (absorbance 405nm). Results represent the mean of 
duplicate experiments (each time point the mean of two replicates). 
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Fig. 1 
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Fig. 2. 
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Figure 3. 
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Figure 4. 
 
 
 
 
 
 
 
 
 
 
CON FFF FFH FHF
FHH HFF HFH HHF
Fluorescence intensity
R
el
a
ti
ve
 c
el
l 
n
u
m
b
er
CD134 utilisation by FIV 
29 
Figure 5. 
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Fig. 6. 
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Figure 7. 
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Table 1.  Comparison of CD134 chimaera utilisation by diverse strains of FIV. 
 
 
 
 
Cell line 
MCC HeLa 
Virus (FH)FH F(FH)H ratio (FH)FH FFHH ratio 
GL8 25 1 25* 1720 10 172* 
PPR 609 241 2.5 4919 2608 1.9 
TM2 82 2 41* 1878 199 9.4* 
CPG41 59 1 59* 2690 10 269* 
0425 3 5 0.6 107 95 1.1 
1419 5 1 5 577 720 0.8 
0827 5 1 5 459 13 35.3* 
B2542 275 85 3.2 302 220 1.3 
NCSU1 49 1 49* 2802 798 3.5 
 
*FIV Env pseudotypes displaying a preference for (FH)FH over F(FH)H. Results are 
typical of two separate experiments. 
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